Developer docs
API playgroundTry for free, no card

Search company profiles

ZyVersa Therapeutics

Full company profile

uuid0000dgh

Namestring
ZyVersa Therapeutics
Legal namestring
ZyVersa Therapeutics, Inc.
Websiteurl
zyversa.com
Company typeenum
Public
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWeston, United States
HQ citystring
Weston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, inflammasome inhibitor therapy, monoclonal antibody drugs, chronic kidney disease therapeutics, inflammatory disease treatment
Industry5 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals - Inflammatory & Renal Disease Therapeutics
No data
Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company developing proprietary drugs for inflammatory and renal diseases. Revenue expected from commercializing IC 100 and VAR 200 upon regulatory approval.

zyversa.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1IC 100
Description

Inflammasome ASC Inhibitor - a humanized monoclonal IgG4 antibody that uniquely inhibits the adaptor ASC component of multiple types of inflammasomes for treating inflammatory disorders

zyversa.com
+1 more record
Core offering1 text field

ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company developing two proprietary first-in-class prescription drug candidates: IC 100, a humanized monoclonal IgG4 antibody that inhibits the ASC adaptor component of multiple inflammasomes to block initiation and perpetuation of the inflammatory cascade, and VAR 200, a 2HPβCD cholesterol efflux mediator that removes pathogenic cholesterol from kidney cells to treat chronic kidney diseases such as FSGS, Alport syndrome, and diabetic kidney disease. The company has not yet received regulatory approval and is pre-revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • IC 100 demonstrated preclinical efficacy in animal models of multiple sclerosis, Parkinson's disease, stroke-related cardiovascular disease, and retinopathy of prematurity
+3 more records
Product overview1 text field

ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company with two proprietary product platforms developed from research at the University of Miami Miller School of Medicine. The company focuses on inflammatory and renal diseases. IC 100 is a humanized monoclonal antibody targeting inflammasome ASC for treatment of inflammatory diseases, with lead indication in cardiometabolic conditions. VAR 200 is a cholesterol efflux mediator targeting renal lipotoxicity for treatment of chronic kidney diseases, with lead indication in focal segmental glomerulosclerosis (FSGS), expanding into Alport syndrome and diabetic kidney disease.

Product and service2 records
1IC 100 - Inflammasome ASC Inhibitor
CategoryBiopharmaceutical - Inflammatory Disease Therapeutics
Description

IC 100 is a humanized monoclonal IgG4 antibody that inhibits the adaptor ASC component of multiple types of inflammasomes (12 or more), blocking inflammasome formation, activation, and initiation of the inflammatory response, and also inhibits ASC Specks to prevent perpetuation of inflammation. It is being developed to treat a broad group of inflammatory disorders including cardiometabolic conditions such as obesity, orphan renal diseases, and CNS and peripheral inflammatory diseases.

2VAR 200 - Cholesterol Efflux Mediator
CategoryBiopharmaceutical - Renal Disease Therapeutics
Description

VAR 200 is a cholesterol efflux mediator using 2-hydroxypropyl-beta-cyclodextrin (2HPβCD) that mediates removal of pathogenic cholesterol and other lipids from kidney cells through both passive and active cholesterol efflux mechanisms, with the active ingredient accumulating in kidneys for excretion into urine. It is in development for treatment of chronic kidney diseases including focal segmental glomerulosclerosis (FSGS), Alport syndrome, and diabetic kidney disease, where it protects against structural damage, reduces proteinuria, and preserves kidney function.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Strategic partnership announced in May 2025 for inhaled therapy co-development. Philips Respironics is a respiratory care company and the partnership involves co-development of inhaled therapies.

Strategic tierCoreTypeTechnology or Integration
Description

Technology/development alliance partner. L&F Research LLC is one of ZyVersa's existing technology and development alliance partners, collaborating on the development of novel therapeutics.

Strategic tierCoreTypeTechnology or Integration
Description

Technology/development alliance partner. InflamaCORE LLC is dedicated to treating and diagnosing inflammatory injury and disease. Several of ZyVersa's scientific advisory board members are founding members of InflamaCORE.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing dapansutrile, an oral NLRP3 inflammasome inhibitor. Direct competitor to ZyVersa's IC 100 in the inflammasome/inflammation space, with overlapping cardiometabolic and inflammatory indications.

TypeDirect peer
Description

UK-based clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors for inflammatory and CNS diseases. Closely comparable mechanism of action and disease focus to ZyVersa's IC 100 inflammasome platform.

3Inflazome (acquired by Roche)
TypeDirect peer
Description

Developed small-molecule NLRP3 inflammasome inhibitors acquired by Roche in 2020. Direct inflammasome-targeting peer; represents the path ZyVersa may follow (acquisition by big pharma) if IC 100 validates clinically.

TypeDirect peer
Description

Developed NLRP3 and cGAS-STING pathway inhibitors acquired by Bristol Myers Squibb. Comparable inflammasome-focused pipeline with similar development-stage characteristics to ZyVersa, demonstrating large-pharma appetite for inflammasome assets.

TypeDirect peer
Description

Commercial-stage rare disease company with sparsentan, an FDA-approved treatment for FSGS and IgA nephropathy. Most direct commercial-stage competitor to ZyVersa's VAR 200 in the renal lipotoxicity/FSGS space.

TypeDirect peer
Description

Swedish biotech with Nefecon (Tarpeyo), an FDA-approved treatment for IgA nephropathy. Comparable clinical-stage-to-commercial renal disease player competing in the same $18B renal market targeted by VAR 200.

TypeDirect peer
Description

Nephrology-focused biotech acquired by Novartis in 2023, developing atrasentan and other renal therapies. Direct peer in chronic kidney disease drug development; acquisition illustrates the partnership/exit dynamic ZyVersa could pursue with VAR 200.

TypeBroad incumbent
Description

Large-cap biopharma with a growing rare renal franchise (e.g., inaxaplin for APOL1-mediated kidney disease). Broad incumbent pursuing renal indications overlapping with VAR 200's target markets, with substantially greater clinical and commercial resources.

TypeEmerging player
Description

Clinical-stage biopharma with a renal disease subsidiary developing treatments for rare kidney disorders. Comparable focus on chronic kidney disease with overlapping patient populations to ZyVersa's VAR 200 program.

TypeOthers
Description

Commercial-stage biopharmaceutical company co-founded by ZyVersa's CEO Stephen Glover. While focused on immuno-oncology rather than inflammasomes, the operational link and similar small-cap specialty pharma structure make it a relevant comparable.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZyVersa Therapeutics

Biopharmaceuticals - Inflammatory & Renal Disease Therapeuticszyversa.com

ZyVersa Therapeutics firmographics

Firmographics
Name
ZyVersa Therapeutics
Legal name
ZyVersa Therapeutics, Inc.
Website
https://zyversa.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

ZyVersa Therapeutics industry classification

Industry
Product category
Biopharmaceuticals - Inflammatory & Renal Disease Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceutical
  • Inflammasome inhibitor therapy
  • Monoclonal antibody drugs
  • Chronic kidney disease therapeutics
  • Inflammatory disease treatment

Where ZyVersa Therapeutics is headquartered

Location

Headquarters

HQ city
Weston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ZyVersa Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company developing proprietary drugs for inflammatory and renal diseases. Revenue expected from commercializing IC 100 and VAR 200 upon regulatory approval.

Distribution channels2 records

Marketing channels3 records

ZyVersa Therapeutics product offering

Product offering

Core offering

ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company developing two proprietary first-in-class prescription drug candidates: IC 100, a humanized monoclonal IgG4 antibody that inhibits the ASC adaptor component of multiple inflammasomes to block initiation and perpetuation of the inflammatory cascade, and VAR 200, a 2HPβCD cholesterol efflux mediator that removes pathogenic cholesterol from kidney cells to treat chronic kidney diseases such as FSGS, Alport syndrome, and diabetic kidney disease. The company has not yet received regulatory approval and is pre-revenue.

Product overview

ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company with two proprietary product platforms developed from research at the University of Miami Miller School of Medicine. The company focuses on inflammatory and renal diseases. IC 100 is a humanized monoclonal antibody targeting inflammasome ASC for treatment of inflammatory diseases, with lead indication in cardiometabolic conditions. VAR 200 is a cholesterol efflux mediator targeting renal lipotoxicity for treatment of chronic kidney diseases, with lead indication in focal segmental glomerulosclerosis (FSGS), expanding into Alport syndrome and diabetic kidney disease.

Differentiator

Problem solved

Functional benefit

Brands

  • IC 100: Inflammasome ASC Inhibitor - a humanized monoclonal IgG4 antibody that uniquely inhibits the adaptor ASC component of multiple types of inflammasomes for treating inflammatory disorders
  • VAR 200

Products and services

  • IC 100 - Inflammasome ASC Inhibitor IC 100 is a humanized monoclonal IgG4 antibody that inhibits the adaptor ASC component of multiple types of inflammasomes (12 or more), blocking inflammasome formation, activation, and initiation of the inflammatory response, and also inhibits ASC Specks to prevent perpetuation of inflammation. It is being developed to treat a broad group of inflammatory disorders including cardiometabolic conditions such as obesity, orphan renal diseases, and CNS and peripheral inflammatory diseases.
  • VAR 200 - Cholesterol Efflux Mediator VAR 200 is a cholesterol efflux mediator using 2-hydroxypropyl-beta-cyclodextrin (2HPβCD) that mediates removal of pathogenic cholesterol and other lipids from kidney cells through both passive and active cholesterol efflux mechanisms, with the active ingredient accumulating in kidneys for excretion into urine. It is in development for treatment of chronic kidney diseases including focal segmental glomerulosclerosis (FSGS), Alport syndrome, and diabetic kidney disease, where it protects against structural damage, reduces proteinuria, and preserves kidney function.

Quantifiable outcome

  • IC 100 demonstrated preclinical efficacy in animal models of multiple sclerosis, Parkinson's disease, stroke-related cardiovascular disease, and retinopathy of prematurity
  • +3 more outcomes

Companies that use ZyVersa Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

ZyVersa Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ZyVersa Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered strategic and core.

  • Philips RespironicsstrategicStrategic or Co-development Partner · 1 May 2025Strategic partnership announced in May 2025 for inhaled therapy co-development. Philips Respironics is a respiratory care company and the partnership involves co-development of inhaled therapies.
  • L&F Research LLCcoreTechnology or IntegrationTechnology/development alliance partner. L&F Research LLC is one of ZyVersa's existing technology and development alliance partners, collaborating on the development of novel therapeutics.
  • InflamaCORE LLCcoreTechnology or IntegrationTechnology/development alliance partner. InflamaCORE LLC is dedicated to treating and diagnosing inflammatory injury and disease. Several of ZyVersa's scientific advisory board members are founding members of InflamaCORE.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

ZyVersa Therapeutics competitors and assessment

Company assessment

Direct peers

  • Olatec Therapeutics: Clinical-stage company developing dapansutrile, an oral NLRP3 inflammasome inhibitor. Direct competitor to ZyVersa's IC 100 in the inflammasome/inflammation space, with overlapping cardiometabolic and inflammatory indications.
  • NodThera: UK-based clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors for inflammatory and CNS diseases. Closely comparable mechanism of action and disease focus to ZyVersa's IC 100 inflammasome platform.
  • Inflazome (acquired by Roche): Developed small-molecule NLRP3 inflammasome inhibitors acquired by Roche in 2020. Direct inflammasome-targeting peer; represents the path ZyVersa may follow (acquisition by big pharma) if IC 100 validates clinically.
  • IFM Therapeutics (acquired by BMS): Developed NLRP3 and cGAS-STING pathway inhibitors acquired by Bristol Myers Squibb. Comparable inflammasome-focused pipeline with similar development-stage characteristics to ZyVersa, demonstrating large-pharma appetite for inflammasome assets.
  • Travere Therapeutics: Commercial-stage rare disease company with sparsentan, an FDA-approved treatment for FSGS and IgA nephropathy. Most direct commercial-stage competitor to ZyVersa's VAR 200 in the renal lipotoxicity/FSGS space.
  • Calliditas Therapeutics: Swedish biotech with Nefecon (Tarpeyo), an FDA-approved treatment for IgA nephropathy. Comparable clinical-stage-to-commercial renal disease player competing in the same $18B renal market targeted by VAR 200.
  • Chinook Therapeutics (acquired by Novartis): Nephrology-focused biotech acquired by Novartis in 2023, developing atrasentan and other renal therapies. Direct peer in chronic kidney disease drug development; acquisition illustrates the partnership/exit dynamic ZyVersa could pursue with VAR 200.

Broad incumbents

  • Vertex Pharmaceuticals: Large-cap biopharma with a growing rare renal franchise (e.g., inaxaplin for APOL1-mediated kidney disease). Broad incumbent pursuing renal indications overlapping with VAR 200's target markets, with substantially greater clinical and commercial resources.

Emerging players

  • BridgeBio Pharma: Clinical-stage biopharma with a renal disease subsidiary developing treatments for rare kidney disorders. Comparable focus on chronic kidney disease with overlapping patient populations to ZyVersa's VAR 200 program.

Others

  • Coherus BioSciences: Commercial-stage biopharmaceutical company co-founded by ZyVersa's CEO Stephen Glover. While focused on immuno-oncology rather than inflammasomes, the operational link and similar small-cap specialty pharma structure make it a relevant comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

ZyVersa Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZyVersa Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

ZyVersa Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZyVersa Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZyVersa Therapeutics

What does ZyVersa Therapeutics do?

ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company developing two proprietary first-in-class prescription drug candidates: IC 100, a humanized monoclonal IgG4 antibody that inhibits the ASC adaptor component of multiple inflammasomes to block initiation and perpetuation of the inflammatory cascade, and VAR 200, a 2HPβCD cholesterol efflux mediator that removes pathogenic cholesterol from kidney cells to treat chronic kidney diseases such as FSGS, Alport syndrome, and diabetic kidney disease. The company has not yet received regulatory approval and is pre-revenue.

Is ZyVersa Therapeutics a public or private company?

ZyVersa Therapeutics is a public company. It is classified as public and is currently operating.

When was ZyVersa Therapeutics founded?

ZyVersa Therapeutics was founded in 2014. It employs 11 to 50 people.

Where is ZyVersa Therapeutics based?

ZyVersa Therapeutics is headquartered in Weston, United States, in the North America region.

How does ZyVersa Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are ZyVersa Therapeutics's main competitors?

Direct peers on record are Olatec Therapeutics, NodThera, Inflazome (acquired by Roche), IFM Therapeutics (acquired by BMS), Travere Therapeutics, Calliditas Therapeutics and Chinook Therapeutics (acquired by Novartis). Vertex Pharmaceuticals is listed as a broad incumbent. BridgeBio Pharma is listed as an emerging player. Coherus BioSciences is listed as an others.

Does ZyVersa Therapeutics have an API?

No public API is recorded for ZyVersa Therapeutics.

What industry is ZyVersa Therapeutics in?

ZyVersa Therapeutics's product category is Biopharmaceuticals - Inflammatory & Renal Disease Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanZVSA Stock Price, News & AnalysisZyVersa Therapeutics' common stock has been delisted from The Nasdaq Capital Market and is now quoted on the OTCQB Venture Market following trading suspension in July 2025. The clinical-stage biopharmaceutical company continues to advance its renal disease drug VAR 200 through phase 2 trials while preparing for IND filings for its inflammatory drug IC 100, relying on equity financing and warrant exercises to fund ongoing operations.BioSpaceZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateZyVersa Therapeutics reported a Q1 2026 net loss of $1.8 million, down from $2.3 million a year earlier. The company plans to file an IND for IC 100 in Q4 2026 and initiate a Phase 2a trial for VAR 200 in H2 2026. It expects to raise additional financing to fund operations.Stock TitanZyVersa Q1 loss $1.8M, cash funds month-to-monthZyVersa Therapeutics reported a Q1 2026 net loss of approximately $1.8 million, representing a 20.5% improvement compared to the $2.3 million loss in Q1 2025, with total operating expenses decreasing by $0.8 million. The company raised $1 million in Q1 2026 but faces a precarious cash position of $0.3 million that will only fund operations on a month-to-month basis, necessitating additional financing to support clinical development milestones including IND filing for IC 100 in Q4 2026 and Phase 2a trial initiation for VAR 200 in H2 2026.GlobeNewswireZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateZyVersa Therapeutics reported Q1 2026 financial results showing a net loss of approximately $1.8 million, representing a 20.5% improvement compared to the $2.3 million net loss in Q1 2025. The company raised $1 million during the quarter and had cash of $0.3 million as of March 31, 2026, which management stated is only sufficient on a month-to-month basis, requiring additional financing to continue operations and advance its pipeline. ZyVersa outlined upcoming value-driving milestones including filing an IND for IC 100 in Q4 2026, initiating a Phase 2a trial for VAR 200 in patients with FSGS and Alport Syndrome in H2 2026, and reporting interim Phase 2a read-outs around Q4 2026.WiseGuy ReportsNitric Oxide Therapy Device Market Size, Share & Trends 2035The Global Nitric Oxide Therapy Device Market was valued at $2,000 million in 2024 and is projected to reach $3,800 million by 2035, growing at a compound annual growth rate of 6.0%. Key recent developments include Nitric Bio's acquisition of Vasomune in March 2025 to accelerate next-generation device development, Philips Respironics' strategic partnership with ZyVersa Therapeutics in May 2025 for inhaled therapy co-development, and Aeris Therapeutics' June 2025 contract win to supply delivery devices to a major national health system. The market is driven by rising respiratory disease prevalence, technological advancements in portable devices, and growing adoption of home healthcare solutions, with North America holding the largest market share.BioSpaceZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateZyVersa Therapeutics reported full year 2025 financial results with a net loss of approximately $25.0 million, driven primarily by an $18.6 million impairment of in-process research and development, compared to a net loss of $9.4 million in 2024. The company ended 2025 with only $0.1 million in cash and expects its current liquidity to fund operations on a month-to-month basis, having raised only $4.1 million in 2025 and an additional $1 million in Q1 2026. ZyVersa is advancing two drug candidates toward key milestones: Inflammasome ASC Inhibitor IC 100 with an IND filing planned for Q4-2026, and Cholesterol Efflux Mediator VAR 200 with a Phase 2a trial in FSGS and Alport Syndrome patients planned for Q2-2026.Stock TitanZyVersa FY2025 net loss hits $25M, needs cashZyVersa Therapeutics reported a net loss of approximately $25 million for full year 2025, more than doubling from the $9.4 million loss in 2024, primarily due to an $18.6 million impairment charge for in-process research and development. The company ended 2025 with only $0.1 million in cash on hand and subsequently raised $1 million in February 2026 via convertible promissory notes, indicating severe liquidity constraints. ZyVersa stated it will need additional financing to fund continuing operations and achieve its stated milestones for its two pipeline programs, IC 100 and VAR 200.GlobeNewswireDelisting of Securities from The Nasdaq Stock MarketNasdaq announced delisting of securities for Digital Brands Group, Lipella Pharmaceuticals, ZyVersa Therapeutics, Crown LNG Holdings, Brainstorm Cell Therapeutics, Wag! Group, Ontrak, TPI Composites, and Embrace Change Acquisition Corp. Each company's securities had been suspended for varying periods and had not traded on Nasdaq since.AInvestZyVersa Therapeutics: A Narrowing GAAP Loss Amid Biotech Turbulence—Turning Point or Temporary Reprieve?ZyVersa Therapeutics narrowed its Q2 2025 GAAP loss by 83% to $(0.73/share), driven by 49.5% R&D and 18.5% G&A cuts. The company holds $0.1M in cash and requires additional financing, with Phase 2a trial data expected in Q4 2025.GlobeNewswireZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D ProgressZyVersa Therapeutics CEO Stephen Glover issued a mid-year shareholder letter detailing recent corporate developments and R&D progress. The company closed $12 million in financing, including a $2M warrant inducement and a $10M partnership with Williamsburg Venture Holdings. It also announced preliminary data for a Phase 2a trial in diabetic kidney disease and plans for an IND-enabling preclinical study in Q3-2025.